204 related articles for article (PubMed ID: 14523472)
21. PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols.
Müller HJ; Beier R; da Palma JC; Lanvers C; Ahlke E; von Schütz V; Gunkel M; Horn A; Schrappe M; Henze G; Kranz K; Boos J
Cancer Chemother Pharmacol; 2002 Feb; 49(2):149-54. PubMed ID: 11862429
[TBL] [Abstract][Full Text] [Related]
22. Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.
Heo YA; Syed YY; Keam SJ
Drugs; 2019 May; 79(7):767-777. PubMed ID: 31030380
[TBL] [Abstract][Full Text] [Related]
23. How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review.
Brigitha LJ; Pieters R; van der Sluis IM
Eur J Cancer; 2021 Nov; 157():238-249. PubMed ID: 34536947
[TBL] [Abstract][Full Text] [Related]
24. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
Rizzari C; Citterio M; Zucchetti M; Conter V; Chiesa R; Colombini A; Malguzzi S; Silvestri D; D'Incalci M
Haematologica; 2006 Jan; 91(1):24-31. PubMed ID: 16434367
[TBL] [Abstract][Full Text] [Related]
25. Pegaspargase: a review of clinical studies.
Graham ML
Adv Drug Deliv Rev; 2003 Sep; 55(10):1293-302. PubMed ID: 14499708
[TBL] [Abstract][Full Text] [Related]
26. Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia.
Vieira Pinheiro JP; Müller HJ; Schwabe D; Gunkel M; Casimiro da Palma J; Henze G; von Schütz V; Winkelhorst M; Würthwein G; Boos J
Br J Haematol; 2001 Apr; 113(1):115-9. PubMed ID: 11328290
[TBL] [Abstract][Full Text] [Related]
27. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE
Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417
[TBL] [Abstract][Full Text] [Related]
28. PEG-linked asparaginase marketed.
Am J Hosp Pharm; 1994 Jun; 51(11):1382. PubMed ID: 7942872
[No Abstract] [Full Text] [Related]
29. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
[TBL] [Abstract][Full Text] [Related]
30. Asparaginases: where do we go from here?
Ettinger LJ
J Pediatr Hematol Oncol; 1999; 21(1):3-5. PubMed ID: 10029804
[No Abstract] [Full Text] [Related]
31. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia.
Appel IM; den Boer ML; Meijerink JP; Veerman AJ; Reniers NC; Pieters R
Blood; 2006 Jun; 107(11):4244-9. PubMed ID: 16497975
[TBL] [Abstract][Full Text] [Related]
32. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.
Avramis VI; Sencer S; Periclou AP; Sather H; Bostrom BC; Cohen LJ; Ettinger AG; Ettinger LJ; Franklin J; Gaynon PS; Hilden JM; Lange B; Majlessipour F; Mathew P; Needle M; Neglia J; Reaman G; Holcenberg JS; Stork L
Blood; 2002 Mar; 99(6):1986-94. PubMed ID: 11877270
[TBL] [Abstract][Full Text] [Related]
33. Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
Vieira Pinheiro JP; Lanversa C; Würthwein G; Beier R; Casimiro da Palma J; von Stackelberg A; Boos J
Leuk Lymphoma; 2002 Oct; 43(10):1911-20. PubMed ID: 12481884
[TBL] [Abstract][Full Text] [Related]
34. Pegaspargase for acute lymphoblastic leukemia.
Med Lett Drugs Ther; 1995 Mar; 37(944):23-4. PubMed ID: 7877556
[No Abstract] [Full Text] [Related]
35. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study.
Appel IM; Kazemier KM; Boos J; Lanvers C; Huijmans J; Veerman AJ; van Wering E; den Boer ML; Pieters R
Leukemia; 2008 Sep; 22(9):1665-79. PubMed ID: 18580955
[TBL] [Abstract][Full Text] [Related]
36. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia.
Dibenedetto SP; Di Cataldo A; Ragusa R; Meli C; Lo Nigro L
J Clin Oncol; 1995 Feb; 13(2):339-44. PubMed ID: 7844595
[TBL] [Abstract][Full Text] [Related]
37. Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar
Würthwein G; Lanvers-Kaminsky C; Hempel G; Gastine S; Möricke A; Schrappe M; Karlsson MO; Boos J
Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):955-963. PubMed ID: 28349335
[TBL] [Abstract][Full Text] [Related]
38. Pegasparaginase: where do we stand?
Zeidan A; Wang ES; Wetzler M
Expert Opin Biol Ther; 2009 Jan; 9(1):111-9. PubMed ID: 19063697
[TBL] [Abstract][Full Text] [Related]
39. Treatment of severe hypertriglyceridemia associated with accidental pegylated asparaginase push in a child with relapsed acute lymphoblastic leukemia.
Malbora B; Avci Z; Ozbek N
Drug Chem Toxicol; 2012 Oct; 35(4):463-6. PubMed ID: 22149271
[TBL] [Abstract][Full Text] [Related]
40. A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors.
Taylor CW; Dorr RT; Fanta P; Hersh EM; Salmon SE
Cancer Chemother Pharmacol; 2001; 47(1):83-8. PubMed ID: 11221967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]